Importantly, we initiated baricitinib therapy on day 3 post‐influenza infection to provide a clinically relevant murine translational study and have demonstrated that baricitinib effectively inhibits JAK/STAT signaling and ISG induction in our model. The gene discussed is SOAT1; the disease is influenza.